JPRN-UMIN000026163已完成1 期
A phase I study of a 5-peptide vaccine with immune modulators for patients with refractory metastatic colorectal cancer - A 5-peptide vaccine with immune modulators for patients with metastatic colorectal cancer
Department of Surgery, Kindai University Faculty of Medicine0 个研究点目标入组 12 人开始时间: 2017年3月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)patient having double cancer 2)patient having interstitial pneumonia 3)patient having brain metastasis 4)patient having mental disorder 5)patient having uncontrollable heart disorder, pulmonary disorder or renal disorder 6)patient having bleeding tendency 7)patient having any allergic reaction to using drugs
研究者
相似试验
已完成
1 期
Phase I clinical study with 5 peptides vaccination in HLA-A2402-positive advanced-stage esophageal cancer patientschemotherapy-resistance unresectable esophageal cancerJPRN-UMIN000004714Tokai University school of medicine9
已完成
1 期
Phase I clinical study of peptide vaccine using novel tumor-associated antigen TTK against advanced esophageal carcinomaAdvanced esophageal cancer refractory to standard therapeutic modalityJPRN-UMIN000001014niversity of Tokyo6
已完成
1 期
Phase I study of peptide-cocktail vaccination for HCV-positive patients with liver cancer who have undergone radical therapy.liver cancerJPRN-UMIN000003773Kurume University Cancer Vaccine Center3
进行中（未招募）
1 期
Anti-tumoral vaccination of melanoma patients with peptides associated with GM-CT-01, a vegetal derived sugar that binds to and blocks galectin, a protein produced by tumor cells that inhibits immune cells.Metastatic melanomaMedDRA version: 14.0Level: LLTClassification code 10025651Term: Malignant melanoma excisionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.0Level: LLTClassification code 10027150Term: Melanoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10042550Term: Superficial spreading melanoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10029488Term: Nodular melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025662Term: Malignant melanoma of skin of scalp and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10056768Term: Malignant melanoma of skin of lower limb, incl hipSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10048434Term: Melanoma malignant aggravatedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10042548Term: Superficial spreading melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10025652Term: Malignant melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018638-29-BECentre du Cancer des Cliniques Universitaires Saint-Luc6
进行中（未招募）
1 期
Phase I/II study of peptide vaccination associated with tumoral immunomodulation with proinflammatory cytokines and imiquimod in patients with advanced metastatic melanomaEUCTR2010-020435-40-BECentre du Cancer3